This company listing is no longer active
5HTA Stock Overview
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Harpoon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$20.80 |
| 52 Week High | US$21.20 |
| 52 Week Low | US$4.86 |
| Beta | 2.1 |
| 1 Month Change | 0.97% |
| 3 Month Change | n/a |
| 1 Year Change | 230.16% |
| 3 Year Change | -87.62% |
| 5 Year Change | -80.41% |
| Change since IPO | -83.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| 5HTA | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 6.5% | 1.3% |
| 1Y | 230.2% | -1.9% | 9.0% |
Return vs Industry: 5HTA exceeded the German Biotechs industry which returned -21.1% over the past year.
Return vs Market: 5HTA exceeded the German Market which returned 4.6% over the past year.
Price Volatility
| 5HTA volatility | |
|---|---|
| 5HTA Average Weekly Movement | 51.8% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 5HTA has not had significant price volatility in the past 3 months.
Volatility Over Time: 5HTA's weekly volatility has increased from 28% to 52% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 53 | Julie Eastland | www.harpoontx.com |
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body’s immune system to treat patients suffering from cancer and other diseases in the United States. The company develops tri-specific T cell activating construct (TriTAC) product candidate, including HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors; and HPN217 that is in Phase I clinical trials for the treatment of multiple myeloma. Its preclinical stage product is HPN601 for the treatment of multiple solid tumor indications.
Harpoon Therapeutics, Inc. Fundamentals Summary
| 5HTA fundamental statistics | |
|---|---|
| Market cap | €450.35m |
| Earnings (TTM) | -€27.90m |
| Revenue (TTM) | €34.16m |
13.2x
P/S Ratio-16.1x
P/E RatioIs 5HTA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 5HTA income statement (TTM) | |
|---|---|
| Revenue | US$37.34m |
| Cost of Revenue | US$58.63m |
| Gross Profit | -US$21.29m |
| Other Expenses | US$9.21m |
| Earnings | -US$30.50m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.43 |
| Gross Margin | -57.02% |
| Net Profit Margin | -81.67% |
| Debt/Equity Ratio | 194.4% |
How did 5HTA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/12 07:55 |
| End of Day Share Price | 2024/03/12 00:00 |
| Earnings | 2023/09/30 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Harpoon Therapeutics, Inc. is covered by 12 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Arlinda Lee | Canaccord Genuity |
| Jennifer Kim | Cantor Fitzgerald & Co. |